tbuckley/cabot-search huggingface dataset:
1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes
Authors: J.E. Medina, E.T. Roussos Torres, A. Leal, V. Adleff, K. Lumbard, L. Keefer, J. Carey, A. Brufsky, P. Lorusso, J.P. Eder, V. Chung, M. Downs, A. O'Connor, R. Piekarz, H. Streicher, E.M. Jaffee, R.B. Scharpf, V. Stearns, R.M. Connolly, V.E. Velculescu
Journal: Annals of Oncology (2022)
1706P Artificial intelligence-powered tumor purity assessment from H&amp;E whole slide images associates with variant allele frequency of somatic mutations across 23 cancer types in TCGA cohorts
Authors: S. Kim, G. Park, S. Kim, S. Song, H. Song, J. Ryu, S. Park, S. Pereira, K. Paeng, C.-Y. Ock
Journal: Annals of Oncology (2022)
1756P Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary
Authors: A.C. Maraz, B. Nagy, T. Macher, J. Jeskó, E. Tischler, C. Csongvai, M. Kearney
Journal: Annals of Oncology (2022)
1495P SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with &gt;2y median follow up
Authors: A. Digklia, A. Kollar, M-N. Kronig, C. Britschgi, T. Rordorf, M. Joerger, F. Krasniqi, Y. Metaxas, I. Colombo, D. Dietrich, S. Chiquet, K. Ribi, C.A. Rothermundt
Journal: Annals of Oncology (2022)
1670P Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)
Authors: L. Tan, B. Tran, J. Tie, E. Link, S.Q. Wong, S. Chandrashekar, J. Guinto, B. Markman, S. Ananda, N.C. Tebbutt, M. Michael, B.J. Solomon, G. McArthur, P. Gibbs, S-J. Dawson, J. Desai
Journal: Annals of Oncology (2022)
1548P Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy
Authors: M. Shirasawa, T. Yoshida, K. Shiraishi, A. Takigami, D. Takayanagi, T. Imabayashi, Y. Matsumoto, K. Masuda, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, T. Tsuchida, R. Hamamoto, N. Yamamoto, N. Motoi, S-I. Watanabe, Y. Ohe
Journal: Annals of Oncology (2022)
1475P Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)
Authors: T. Zhang, M. Poellmann, S-J. Park, J. Bu, R. Zhao, Q. Zhou, A. Agarwal, J. Parks, M. Reyes-Martinez, A.J. Armstrong, D.J. George, A.Z. Wang, S. Hong
Journal: Annals of Oncology (2022)
1554MO Perspectives of patients with metastatic breast cancer on exercise interventions: Results from a survey in five European countries
Authors: M. Sweegers, J. Depenbusch, N. Aaronson, Y. Wengström, M. Backman, N. Gunasekara, D. Clauss, M. Pelaez, M. Lachowicz, A.M. May, K. Steindorf, M. Stuiver
Journal: Annals of Oncology (2022)
1745P Phase II study of neoadjuvant chemotherapy with 4 cycles of dose dense MVAC followed by radical surgery in Korean patients with MIBC and locally advanced urothelial carcinoma of bladder (NCT04047693)
Authors: K. Park, J.K. Nam, H.J. Lee, T.U. Kim, H. Ryu, Y.K. Ki, J-J. Kim, S.B. Oh, S.Y. Oh, Y.J. Hong
Journal: Annals of Oncology (2022)
1493MO Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)
Authors: E.F. Nassif, E.Z. Keung, P. Jiang, A. Reuben, S. Crosby, G. Mathew, A. Lazar, K. Torres, W-L. Wang, A. Guadagnolo, A. Bishop, K.K. Hunt, J. Bird, V. Lewis, A.P. Conley, J.A. Wargo, N. Somaiah, C.L. Roland
Journal: Annals of Oncology (2022)
1458P Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)
Authors: D. Cella, C.G. Porta, M. Hamilton, F. Ejzykowicz, S.I. Blum, C. Ivanescu, C. Suarez Rodriguez, T.K. Choueiri, R.J. Motzer
Journal: Annals of Oncology (2022)
1367P JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study
Authors: E. Calvo, B. Doger de Spéville, J. Carles Galceran, A. Peer, D.L. Sarid, B.J. Eigl, A. Avadhani, D. Yao, V. Lin, S. Wu, P. Jaiprasart, J. Loffredo, M. Tamegnon, H. Xie, A.R. Hansen
Journal: Annals of Oncology (2022)
1705P HER2 intratumoral genetic and non-genetic heterogeneity in metastatic colorectal cancer
Authors: K. Sawada, H. Nitta, Y. Nakamura, W. Okamoto, H. Taniguchi, Y. Komatsu, H. Hara, T. Kato, T. Nishina, T. Ohta, T. Esaki, T. Yoshino, S. Fujii
Journal: Annals of Oncology (2022)
1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort
Authors: S. Cousin, C. Bellera, None J-P. Guegan, T. Valentin, R. Bahleda, J-P. Metges, P.A. Cassier, C. Cantarel, M. Spalato Ceruso, M. Kind, I. Soubeyran, J. Palussiere, A. Bessede, A. Italiano
Journal: Annals of Oncology (2022)
1504P Real-world treatment patterns and outcomes of metastatic synovial sarcoma over the last decade in England
Authors: S.J. Strauss, P. Hindocha, S. Hitov, S.M. Benson, H. Galante, S. Georgiev, S. Lay-Flurrie, M.J. Schoemaker, S.L. McGuigan, C. Lunt, E. Van Winkle, S. Biswas
Journal: Annals of Oncology (2022)
1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies
Authors: P.S. Deshmukh, I. De Kouchkovsky, L. Zhang, T. Jindal, K. Reyes, E. Hernandez Romero, E. Chan, A. Desai, H.T. Borno, D. Kwon, A. Wong, R. Bose, R. Aggarwal, S. Porten, L. Fong, E.J. Small, J. Chou, T. Friedlander, V.S. Koshkin
Journal: Annals of Oncology (2022)
1660O Dual immune checkpoint blockade induces analogous alterations in the intratumoral CD8+ T cell and Treg compartments
Authors: J.J.H. Traets, A.M. van der Leun, J.L. Vos, J.B.W. Elbers, S. Patiwael, X. Qiao, M. Machuca-Ostos, D.S. Thommen, J.B.A.G. Haanen, T.N. Schumacher, C.L. Zuur
Journal: Annals of Oncology (2022)
1508P Pre-treatment high serum alkaline phosphatase level as a prognostic factor for patients with localized extremity osteosarcoma: A retrospective analysis of adolescent and adult patients
Authors: A. Durnali, N. Alkış, A. Inal, F. Ardıç Yükrük, M.M. Seker, T. Akman, M. Polat Inanc, O. Bal, B.O. Oksuzoglu
Journal: Annals of Oncology (2022)
1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)
Authors: C. Alves Costa Silva, G. Piccinno, L. Cerbone, V. Iebba, E. Colomba, R. Flippot, None C. Sow, I. Darik, A. Maltez Thomas, N. Naoun, A. Bernard-Tessier, A. Reni, N. Segata, B. Escudier, L. Zitvogel, L. Albiges, L. Derosa
Journal: Annals of Oncology (2022)
1556MO The iBLAD study: Patient-reported outcomes in bladder cancer during oncological treatment: A multicenter national randomized controlled trial
Authors: G.A. Taarnhøj, C. Johansen, A. Carus, R.H. Dahlrot, L.H. Dohn, H. Lindberg, H. Pappot
Journal: Annals of Oncology (2022)
1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis
Authors: M. Filetti, P. Lombardi, R. Falcone, D. Giannarelli, A. Carcagnì, R. Giusti, G. Scambia, G. Daniele
Journal: Annals of Oncology (2022)
1481TiP A prospective, randomized phase II trial of neoadjuvant immunotherapy in primary clear cell renal cancer at risk for recurrence or distant metastases: The NESCIO trial
Authors: F.H. Burgers, N.M. Graafland, B.W. Lagerveld, A.E.C. Ruiter, H.P. Beerlage, J.R.J.A. van Moorselaar, P.J. Zondervan, C.T. Mellema, S.P. Rynja, M.L. van Montfoort, S.F. Zerp, M.I. Lopez-Yurda, C.U. Blank, A. Bex, J.B.A.G. Haanen
Journal: Annals of Oncology (2022)
1393P Comparison of genomic alterations (GA) landscape in SPOP mutated (SPOPmut) and SPOP wild type (SPOPwt) clinically advanced prostate cancer (CAPC)
Authors: G. Bratslavsky, P.E. Spiess, P. Grivas, J. Jacob, A. Necchi, N.A. Danziger, D.C. Pavlick, H. Tukachinsky, R.P. Graf, J.S. Ross
Journal: Annals of Oncology (2022)
1719P Predictive value of DNA repair gene alterations for the response to platinum-based chemotherapy and immunotherapy in advanced solid tumors patients: Results from a single center molecular screening program
Authors: C. Chabot, S. Cousin, E. Khalifa, M. Spalato Ceruso, I. Soubeyran, None Y. laizet, A. Crombe, A. Italiano
Journal: Annals of Oncology (2022)
1484O Deep learning predicts patients’ outcome and mutations from H&amp;E slides in gastrointestinal stromal tumor (GIST)
Authors: A. Italiano, Y. Fu, M. Karanian, R. Perret, A. Camara, F. Le Loarer, M. Jean-Denis, I. Hostein, A. Michot, F. Ducimetiere, A. Giraud, J-B. Courreges, K. Courtet, Y. Laizet, J.O. du Terrail, B. Schmauch, C. Maussion, J-Y. Blay, J.M. Coindre
Journal: Annals of Oncology (2022)
1518P An individualized model-based risk score is the best prognostic tool for localized soft tissue sarcoma (STS) cases, but clinical status cannot be neglected
Authors: P. Teterycz, H.M. Kosela Paterczyk, P. Jagodzinska-Mucha, A. Mariuk-Jarema, P. Sobczuk, K. Kozak, P. Rogala, M. Wagrodzki, T. Switaj, W. Łysikowska, None A. klimczak, P. Rutkowski
Journal: Annals of Oncology (2022)
1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany
Authors: P. Barthelemy, J. Bedke, L. Albiges, V. Grünwald, B. Escudier, H. Mueller-Huesmann, Y-A. Vano, P. Ivanyi, P. Bigot, E. von der Heyde, B. Narciso, H. Belz, S. Nere, C. Quentric, F. Brellier, M. Herber, A. Thiery-Vuillemin, M-O. Grimm
Journal: Annals of Oncology (2022)
1639P MACADAM (MesotheliomA ClinicAl DatA platforM): A reference database as a tool for large-scale collaborative research
Authors: L. Cerbone, G. Cunietti, S. Delfanti, A.M. De Angelis, M. Lia, M. Venturelli, A. Mazzucco, D. Ricci, F. Grosso
Journal: Annals of Oncology (2022)
1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Authors: A. Chehrazi-Raffle, R. Muddasani, N. Dizman, J. Hsu, L. Meza, Z.B. Zengin, J. Malhotra, N. Chawla, Y.M. Lyou, T. Dorff, T. Contente-Cuomo, D. Dinwiddie, B. McDonald, J. Trent, M. Murtaza, S.K. Pal
Journal: Annals of Oncology (2022)
1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results
Authors: D. Isla, E. Arriola, M.R. Garcia Campelo, P. Diz Tain, C. Marti Blanco, M.M. Lopez-Brea Piqueras, A.L. Moreno Vega, L.A. Leon Mateos, J.M. Oramas Rodriguez, V. Gutierrez Calderon, M. Majem Tarruella, A. Sanchez Hernandez, C. Aguado de la Rosa, R. Alvarez Cabellos, J.L. Marti Ciriquian, A. Moreno Paul, J.L. Firvida Perez, Á. Callejo Mellén, L. Baez, L. Paz-Ares
Journal: Annals of Oncology (2022)
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France
Authors: M.S. Negrier, F.P. Colrat, J. Bonastre, C. Chamielec, S. Teitsson, C. Knight, L. Ni, J. Chevalier, A-F. Gaudin, M. Roupret, S. Branchoux
Journal: Annals of Oncology (2022)
1738P Three-year follow-up update and survival outcomes of the PURE-01 study
Authors: T.C.D. Padua, G. Basile, M. Bandini, D. Raggi, L. Marandino, P. Giannatempo, R. Colombo, M. Colecchia, R. Lucianò, M. Moschini, A. Briganti, F. Montorsi, A. Necchi
Journal: Annals of Oncology (2022)
1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)
Authors: J.W. Avitia, J.L. Bailen, N.D. Shore, R.F. Tutrone, L.T. Nordquist, J. Walling, L. Peterson, R. Schotzinger, W.R. Moore
Journal: Annals of Oncology (2022)
1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers
Authors: C. Paratore, M.V. Pacchiana Parravicini, O. Cantale, F. Carfì, C. Zichi, T. Gamba, D. Pignataro, A. Samuelly, M. Tucci, M. Di Maio, S. Novello
Journal: Annals of Oncology (2022)
449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study
Authors: C. Tron, F. Lemaitre, C. Locher, T. Lecomte, C. Tournigand, K. Bouhier Leporrier, S. Le Sourd, J-P. Metges, D. Tougeron, F. Di Fiore, C. Hervé, M. Heran, Y. Touchefeu, B.J-C. Rousseau, A. Hulin, A. Lievre
Journal: Annals of Oncology (2022)
1743P ALTN-AK105-II-02 cohort 4: A phase II study of penpulimab plus anlotinib in patients (pts) with previously treated locally advanced or metastatic urothelial carcinoma (UC)
Authors: Y. Sun, W. Qu, M. Sun, J. Zhou, X. Bi, A. Zhou
Journal: Annals of Oncology (2022)
649TiP A phase I/Ib study evaluating the safety, pharmacokinetics, and preliminary efficacy of LP-118 in subjects with relapsed or refractory haematological malignancies
Authors: E. Curran, J. Byrd, W. Stock, M. Foster, F. Tan, Y. Chen, S.P. Anthony, A. Chen
Journal: Annals of Oncology (2022)
1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer
Authors: N. Menssouri, Y. Wesseling-Rozendaal, L. Poiraudeau, C. Helissey, L. Bigot, J. Sabio, T. Ibrahim, C. Nicotra, L. Tselikas, E. Colomba, P. Lavaud, B. Besse, J-Y. Scoazec, E. den Biezen, S. Neerken, K. Fizazi, D. Gautheret, P. van de Wiel, Y. Loriot
Journal: Annals of Oncology (2022)
1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
Authors: M. Linch, C. Ferrario, M. Stoeckle, B. Laguerre, J.A. Arranz Arija, T. Todenhöfer, P.C. Fong, J.M. Piulats Rodriguez, W. Berry, U. Emmenegger, L. Mourey, N. Mar, L.J. Appleman, A. Joshua, H.J. Conter, X.T. Li, C. Schloss, C.H. Poehlein, J.S. de Bono, E.Y. Yu
Journal: Annals of Oncology (2022)
1535P Efficacy and safety of amrubicin after treatment with immune checkpoint inhibitor combined with chemotherapy in extensive-stage small cell carcinoma: MiSSION1
Authors: T. Nishimura, H. Fujimoto, T. Fujiwara, K. Ito, A. Fujiwara, H. Yuda, H. Itani, C.N. D'Alessandro-Gabazza, E.C. Gabazza, T. Kobayashi
Journal: Annals of Oncology (2022)
1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
Authors: B. Escudier, R.J. Motzer, M. Dyer, J.R. May, F. Ejzykowicz, M. Kurt, C-W. Lee, P. Wang, E. Testa, D.J. Sharpe, S. George, N. Tannir
Journal: Annals of Oncology (2022)
1581P Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors (ICIs): Pooled analysis of individual cases from multiple institutions and literature
Authors: A. Boutros, A. Bottini, G. Rossi, E.T. Tanda, F. Spagnolo, G. Barletta, P. Fava, A. Parisi, None F. de Rosa, M. Palla, R. Marconcini, M. Grandis, P. Spallarossa, M. Sarocchi, E. Arboscello, L. Del Mastro, P. Pronzato, C. Genova
Journal: Annals of Oncology (2022)
1685P Oncogenic activity of recurrent ERBB4 mutations and their sensitivity to neratinib
Authors: V.K. Ojala, A. Tuohisto-Kokko, S. Ahonen, A. Jokilammi, O. Esparta Gonzalez, P. Suominen, D. Chakroborty, T. Airenne, M.J. Johnson, L.D. Eli, K.J. Kurppa, K. Elenius
Journal: Annals of Oncology (2022)
1489MO A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial
Authors: C. Serrano, C.M. Valverde Morales, J. Cruz Jurado, J. Martinez Trufero, J. Martinez-Garcia, S. Roche, A. Redondo Sanchez, M. Giuppi, B. Suarez, C. Romagosa, V. Martinez
Journal: Annals of Oncology (2022)
1471P Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma
Authors: W. Xu, V. Gaborieau, S. Niman, A. Mukeriya, D. Zaridze, N. Singla, M. Freedman, D.F. McDermott, T.K. Choueiri, P. Catalano, V. Sabbisetti, P. Brennan, R. Bhatt
Journal: Annals of Oncology (2022)
443TiP Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120)
Authors: A. Stahler, K. Heinrich, S. Stintzing, I. Jelas, J. Pratschke, W. Schöning, M. Angele, J. D'Haese, B. Gebauer, M. Seidensticker, F. Streitparth, W.G. Kunz, S.D. Corradini, C. Stromberger, U. Vehling-Kaiser, D. Zhang, A. Kurreck, A.H.S. Alig, D.P. Modest, V. Heinemann
Journal: Annals of Oncology (2022)
1376P Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer: Exploratory analysis of LATITUDE study
Authors: S. Roy, C. Wallis, S.C. Morgan, Y. Sun, A.U. Kishan, D. Mukherjee, D.E. Spratt, F. Saad, S. Malone
Journal: Annals of Oncology (2022)
1614P Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake
Authors: M. Nguyen, N.T. Bain, L. Grech, A. Kwok, N. Hamad, A. Tognela, B.A. Chan, L.M. Nott, S. Harris, N.M.H. Chau, C.R. Underhill, D. Day, A. McCartney, K. Webber, E. Segelov
Journal: Annals of Oncology (2022)
1642TiP ENSURE: Dendritic cell therapy (MesoPher) in combination with extended-pleurectomy/decortication after chemotherapy in subjects with resectable mesothelioma: A feasibility study
Authors: L. Cantini, M.V. Dietz, R.A. Belderbos, R. Cornelissen, D.W. Dumoulin, M. Vink, K. Bezemer, A.W. Langerak, J. von der Thüsen, E.A.F. Mahtab, L.P.W.M. Maat, R. Stadhouders, R. Hendriks, M. Willemsen, J.G. Aerts
Journal: Annals of Oncology (2022)
1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
Authors: J-Y. Blay, H. Gelderblom, P. Rutkowski, A. Wagner, M. van de Sande, A. Falcon Gonzalez, S. Stacchiotti, A. Le Cesne, T. Alcindor, C. Serrano, E. Palmerini, V. Ravi, A. Casado Herraez, B. Seddon, M. Vallee, R. Jarecha, M. Sharma, R. Ruiz-Soto, M.L. Sherman, W.D. Tap
Journal: Annals of Oncology (2022)
1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
Authors: M.I. Hu, V. Subbiah, A.S. Mansfield, M. Taylor, M.H.H. Schuler, V. Zhu, J. Hadoux, G. Curigliano, L.J. Wirth, E. Garralda, D.R. Adkins, Y. Godbert, M-J. Ahn, P.A. Cassier, B.C. Cho, C-C. Lin, T. Barata, A. Zalutskaya, A. Scalori, M.S. Brose
Journal: Annals of Oncology (2022)
1696O Genomic profiling and molecular targeting of lung cancer brain metastases
Authors: H. Cheng, M. Feng, N. Fan, E.S. Sokol, F. Wang, None Y. Zou, B. Farran, J.S. Ross, G.M. Frampton, T.D. Bhagat, A. Verma, R. Perez-Soler, B. Halmos
Journal: Annals of Oncology (2022)
1453P Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
Authors: D.F. McDermott, T.K. Choueiri, S. Tykodi, J. Merchan, A. Roy, R. Perini, D. Vickery, T. Bauer
Journal: Annals of Oncology (2022)
1604P Assessing lung cancer patients' unplanned hospitalizations, a cohort study to find care gaps: Tracking what is trackable
Authors: J.C. Sanchez, B. Nunez Garcia, M. Blanco Clemente, B. Cantos, V. Calvo de Juan, M. Mendez Garcia, R. Aguado, D.I. Ruiz de Domingo, M.M. Sánchez del Corral, M. Provencio Pulla
Journal: Annals of Oncology (2022)
446TiP Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
Authors: K. Yamazaki, H. Satake, A. Takashima, J. Mizusawa, T. Kataoka, H. Fukuda, Y. Ishizuka, Y. Suwa, K. Numata, N. Shibata, M. Asayama, M. Yokota, T. Tsushima, T. Ohta, T. Yamaguchi, T. Hamaguchi, Y. Kanemitsu
Journal: Annals of Oncology (2022)
1633P The correlation between the geographical distribution of asbestos-exposed workplaces and the increased risk of developing malignant mesothelioma, lung cancer, laryngeal cancer, and ovarian cancer: A nationwide population-based analysis in Japan
Authors: A. Saito, H. Charvat, T. Shimoi, T. Matsuda, K. Yonemori
Journal: Annals of Oncology (2022)
1651P Comparison of surgical outcomes between synchronous lateral neck dissection and metachronous lateral neck dissection for clinically N1b papillary thyroid cancer
Authors: H.J. Yun, J.S. Lee, J.S. Lee, S-M. Kim, H.J. Chang, Y.S. Lee, H.S. Chang, C.S. Park
Journal: Annals of Oncology (2022)
1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis
Authors: M. Glaser, C. von Levetzow, S. Michels, L. Nogova, M. Katzenmeier, C. Wömpner, J. Schmitz, E. Bitter, I. Terjung, E. Passmann, D. Schaufler, A.K. Eisert, R.N. Fischer, R. Riedel, J-P. Weber, S. Hahne, S. Merkelbach-Bruse, R. Büttner, J. Wolf, M. Scheffler
Journal: Annals of Oncology (2022)
1427P The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden
Authors: B. Ginman, S. Pahnke, E. Freyhult, T. Hoffman, L. Kolstad, B. Rönnberg, Å. Lundkvist, K. Hamberg, G. Enblad, I. Glimelius
Journal: Annals of Oncology (2022)
1466P Efficacy of immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC) venous tumor thrombus (VTT) shrinkage
Authors: J. Thouvenin, P. Bigot, N. Martinez Chanza, V. Gaillard, R. Cazzato, P. Boudier, D. Maillet, R. Boissier, P. Barthelemy
Journal: Annals of Oncology (2022)
275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
Authors: A. Bardia, K. Punie, C.H. Barrios, A. Schneeweiss, X. Zhai, None D.H. Huynh, N. Vaksman, C. Lai, S.M. Tolaney
Journal: Annals of Oncology (2022)
1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
Authors: C. Sternberg, P. Squifflet, S. Burdett, D. Fisher, E.D. Saad, M. Kurt, S. Teitsson, J.R. May, M. Stoeckle, F. Torti, R. Cote, S. Groshen, E. Ruggeri, A. Zhegalik, J. Tierney, L. Collette, T. Burzykowski, M.E. Buyse
Journal: Annals of Oncology (2022)
1577P Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus
Authors: F. Selle, F. Scotté, J-J. Boffa, G. Etienne, A. Angelergues, P. Augereau, D. Berton-Rigaud, P. Dielenseger, M. Fabbro, C. Falandry, P. Follana, L. Gladieff, F. Joly Lobbedez, J.E. Kurtz, C. Matta, M.A. Mouret Reynier, A. Schmitt, C. Marjollet, A. Floquet
Journal: Annals of Oncology (2022)
1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
Authors: D.C.C. Guven, F.G. Gulbahce Incesu, H.C. Yildirim, E. Erul, E. Chalabiyev, B.Y. Aktas, D. Yuce, Z. Arik, S. Kilickap, S. Aksoy, M. Erman, K.M. Hayran, S. Unal, A. Alp, O. Dizdar
Journal: Annals of Oncology (2022)
1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)
Authors: V. Navani, M.S. Ernst, K. Takemura, S.K. Pal, T.B. Powles, F. Donskov, J.C. Wells, C.K. Kollmannsberger, B. Beuselinck, A.S. Alva, A.J. Weickhardt, A-K. Lalani, D.S. Ernst, N. Agarwal, T.K. Choueiri, D.Y.C. Heng
Journal: Annals of Oncology (2022)
1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)
Authors: M. Sebastian, M. Reck, R.N. Fischer, D.C.C. Christoph, C. Bernhardt, E. von der Heyde, A. Nusch, P. Ludwig, A. Hipper, J. Hanselmann, T. Medinger, A. Binninger, M. Jänicke, P. Christopoulos, C. Elender, A. Bethge, B. Seese, T.C. Gauler, C. Waller
Journal: Annals of Oncology (2022)